Lithium withdrawal in bipolar disorder: Implications for clinical practice and experimental therapeutics research

American Journal of Therapeutics

Volumn 3, Issue 7, 1996, Pages 492-496

  Baldessarini, Ross J ^a   Suppes, Trisha ^b   Tondo, Leonardo ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

bipolar disorder; drug discontinuation; lithium; maintenance therapy; manic depressive illness

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; LITHIUM; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; DRUG WITHDRAWAL; HUMAN; MAINTENANCE THERAPY; MANIC DEPRESSIVE PSYCHOSIS; MORBIDITY; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0029774562     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199607000-00004     Document Type: Article

References (40)

1. Rothman KJ, Michels KB: The continuing unethical use of placebo controls. N Engl J Med 1994;331:294-298.
2. Taubes G: Use of placebo controls in clinical trials disputed. Science 1995;267:25-26.
3. Jeste DV, Gilbert PL, McAdams LA, Harris MJ: Considering neuroleptic maintenance and taper on a continuum: need for individual rather than dogmatic approach. Arch Gen Psychiatry 1995;52:209-212.
4. Baldessarini RJ: Antimanic and mood-stabilizing agents. In: Chemotherapy in Psychiatry: Principles and Practice, Harvard University Press, Cambridge, MA, 1985.
5. Goodwin FK, Jamison KR: Manic-Depressive Illness, Oxford University Press, New York, 1990.
6. Prien RE, Kocsis JH: Long-term treatment of mood disorders. In: Psychopharmacology: The Fourth Generation of Progress (Eds. Bloom FE, Kupfer DJ), Raven Press, New York, 1995, pp. 1067-1079.
7. Baldessarini RJ: Drugs and the treatment of psychiatric disorders: antimanic and antidepressant agents. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics (Eds. Harden W, Rudin W, Molinoff PB, Rall T), McGraw-Hill, New York, (in press).
8. Baldessarini RJ, Tondo L, Suppes T, Faedda GL, Tohen M: Pharmacological treatment of bipolar disorder throughout the life-cycle. In: Bipolar Disorder Through the Life-Cycle (Eds. Shulman K, Tohen M, Kutcher S), John Wiley & Sons, New York, (in press).
9. Suppes T, Baldessarini RJ, Faedda GL, Tohen M: Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48: 1082-1088.
10. Suppes T, Baldessarini RJ, Faedda GL, Tondo L, Tohen M: Discontinuing maintenance treatment in bipolar manicdepression: risks and implications. Harvard Rev Psychiatry 1993;1:131-144.
11. Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M: Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar mood disorders. Arch Gen Psychiatry 1993;50:448-455.
12. Baldessarini RJ: Risks and implications of interrupting maintenance psychotropic drug therapy. Psychother Psy-chosom 1995;63:137-141.
13. Baldessarini RJ, Suppes T, Tondo L, Faedda GL, Viguera A, Tohen M: Risks of interrupting maintenance therapy with psychotropic drugs. Directions Psychiatry 1995; 15(11):1-8.
14. Post RM, Leverich GS, Altshuler L, Mikalauskas K: Lithium discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 1992;149:1727-1729.
15. Müller-Oerlinghausen B, Müser-Causemann B, Volk J: Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992;25:261-270.
16. Tondo L, Baldessarini RJ, Silvetti F, Tohen M, Rudas N: Suicidal behavior in manic-depressive patients with and without lithium maintenance treatment [abstract.]. Proceedings of the International Aretaeus Association Symposium on Prophylaxis of Manic-Depressive Illness, 1994.
17. Tondo L, Baldessarini RJ, Rudas N: Outcome of lithium discontinuation in bipolar disorders, [abstract.] Proceedings of the Second International Conference on New Directions in Affective Disorders, 1995.
18. Waters B, Lapierre Y, Gagnon A, Cahudhry R, Tremblay A, Sarantidis D, Gray R: Determination of the optimal concentration of lithium for the prophylaxis of manicdepressive disorder. Biol Psychiatry 1982;17:1323-1329.
19. Gelenberg AJ, Kane JM, Keller MB, Lavori PW, Rosenbaum JF, Cole K, Lavelle J: Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989;321:1489-1493.
20. Rosenbaum JF, Sachs GS, Lafer B, Kane JM, Gelenberg AJ: High rates of relapse in bipolar patients abruptly changed from standard to low serum lithium levels in a double blind trial, [abstract.] Proceedings of the Annual Meeting of the New Clinical Drug Evaluations Units (NCDEU) of the National Institute of Mental Health, 1992.
21. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, Johnson WE: Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 1984;41:1096-1104.
22. Shapiro DR, Quitkin FM, Fleiss JL: Response to maintenance therapy in bipolar illness. Arch Gen Psychiatry 1989;46:401-105.
23. Wehr TA, Goodwin FK: Rapid cycling in manicdepressives induced by tricyclic antidepressants. Arch Gen Psychiatry 1979;36:555-559.
24. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L: Course of the manic-depressive cycle and changes caused by treatments. Neuropsychopharmakologie 1980;13:156-167.
25. Stoll AL, Banov M, Kolbrener M, Goldstein E, Suplit B, Lucier J, Cohen BM, Tohen M: Antidepressant-associated mania. Am J Psychiatry 1994;151:1642-1645.
26. Mirin SM, Schatzberg AF, Creasey DE: Hypomania and mania after withdrawal of tricyclic antidepressants. Am J Psychiatry 1981;138:87-89.
27. Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ: Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-773.
28. Frank E, Kupfer DJ, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ: Comparison of full-dose vs. half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993;27:139-145.
29. Baldessarini RJ, Gardner DM, Carver DL: Conversions from clozapine to other antipsychotics. Arch Gen Psychiatry (in press).
30. Baldessarini RJ, Viguera A: Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52:189-192.
31. Woods JH, Katz JL, Winger G: Abuse liability of benzodiazepines. Pharmacol Rev 1987;39:251-413.
32. Salzman C (Ed). Task Force Report: Benzodiazepine Dependence, Toxicity, and Abuse, American Psychiatric Association, Washington, DC, 1990.
33. Lader M: Benzodiazepines: a risk-benefit profile. CNS Drugs 1994;1:377-387.
34. Rail TW, Schleifer LS: Drugs effective in the therapy of the epilepsies. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics (Eds. Gilman AG, Rall TW, Nies AS, Taylor P), McGraw-Hill, New York, 1990, pp. 436-462.
35. Dilsaver SC: Heterocyclic antidepressant, monoamine oxidase inhibitor and neuroleptic withdrawal phenomena. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 137-161.
36. Chouinard G, Jones BD: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacological characteristics. Am J Psychiatry 1980;137:16-31.
37. Cohen BM, Baldessarini RJ: Tolerance to therapeutic effects of antidepressants. Am J Psychiatry 1985;142:489-490.
38. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML: A reevaluation of risk of in utero exposure to lithium. J Am Med Assoc 1994;271:146-150.
39. Rangno RE, Langlois S: Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol. Am Heart J 1982;104:473-478.
40. Baldessarini RJ, Tarsy D: Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia. Int Rev Neurobiology 1979;21:1-45.